PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition

Proceedings of the National Academy of Sciences of the United States of America
Dipak PanigrahyMark W Kieran

Abstract

Angiogenesis and inflammation are central processes through which the tumor microenvironment influences tumor growth. We have demonstrated recently that peroxisome proliferator-activated receptor (PPAR)alpha deficiency in the host leads to overt inflammation that suppresses angiogenesis via excess production of thrombospondin (TSP)-1 and prevents tumor growth. Hence, we speculated that pharmacologic activation of PPARalpha would promote tumor growth. Surprisingly, the PPARalpha agonist fenofibrate potently suppressed primary tumor growth in mice. This effect was not mediated by cancer-cell-autonomous antiproliferative mechanisms but by the inhibition of angiogenesis and inflammation in the host tissue. Although PPARalpha-deficient tumors were still susceptible to fenofibrate, absence of PPARalpha in the host animal abrogated the potent antitumor effect of fenofibrate. In addition, fenofibrate suppressed endothelial cell proliferation and VEGF production, increased TSP-1 and endostatin, and inhibited corneal neovascularization. Thus, both genetic abrogation of PPARalpha as well as its activation by ligands cause tumor suppression via overlapping antiangiogenic pathways. These findings reveal the potential utility of the well tol...Continue Reading

References

Nov 18, 1971·The New England Journal of Medicine·J Folkman
Nov 7, 1996·Nature·P R DevchandW Wahli
Feb 26, 2000·Journal of Medicinal Chemistry·T M WillsonB R Henke
Apr 18, 2001·The Journal of Clinical Investigation·K TordjmanC F Semenkovich
Jan 31, 2002·Annual Review of Medicine·Joel Berger, David E Moller
Jun 11, 2002·Biochemical and Biophysical Research Communications·Stephan GoetzeMichael Gräfe
Aug 31, 2002·Molecular Carcinogenesis·Kate M SuchanekSarah J Roberts-Thomson
Oct 9, 2002·The Journal of Clinical Investigation·Dipak PanigrahyArja Kaipainen
Oct 16, 2002·The Journal of Biological Chemistry·Hélène DuezBart Staels
Oct 26, 2002·Journal of the American Academy of Dermatology·Rakhshandra TalpurMadeleine Duvic
Dec 20, 2002·Nature·Lisa M Coussens, Zena Werb
May 21, 2003·American Journal of Therapeutics·Robert P DellavalleLisa M Schilling
Jun 6, 2003·Cellular and Molecular Life Sciences : CMLS·J VaretC Soria
Jan 7, 2004·Nature Reviews. Cancer·Liliane MichalikWalter Wahli
Mar 17, 2004·Molecular Cell·Amir AbdollahiPeter E Huber
Jun 2, 2004·Nature Reviews. Cancer·Robert S Kerbel, Barton A Kamen
Jul 28, 2004·Archives of Dermatological Research·Maja GrabackaAndrzej Slominski
Aug 19, 2004·International Journal of Cancer. Journal International Du Cancer·Marina MaggioraRosa Angela Canuto
Sep 20, 2005·Pharmacology & Therapeutics·Leonardo A MoraesDavid Bishop-Bailey
Nov 12, 2005·Journal of Pediatric Hematology/oncology·Mark W KieranJudah Folkman
Mar 3, 2006·The Journal of Clinical Investigation·Philippe LefebvreBart Staels
May 19, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maja GrabackaKrzysztof Reiss
Oct 28, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Laura PiquerasDavid Bishop-Bailey
Mar 1, 2007·PloS One·Arja KaipainenDipak Panigrahy
Apr 14, 2007·Molecular Cancer Therapeutics·Yoshihito YokoyamaHideki Mizunuma

❮ Previous
Next ❯

Citations

Oct 20, 2011·Cancer Metastasis Reviews·Dipak PanigrahyDarryl C Zeldin
Apr 3, 2013·European Journal of Pharmacology·Janine L BakkerHenk Verheul
Jul 17, 2008·Nature Clinical Practice. Cardiovascular Medicine·Bart StaelsAlberto Zambon
Feb 10, 2012·Nature Reviews. Cancer·Jeffrey M PetersFrank J Gonzalez
Jul 31, 2013·Proceedings of the National Academy of Sciences of the United States of America·Dipak PanigrahyMark W Kieran
Nov 1, 2012·Neuro-oncology·Dana Greene-Schloesser, Mike E Robbins
May 4, 2010·Clinical Obstetrics and Gynecology·Jani R Jensen, Charles C Coddington
Jul 23, 2008·PPAR Research·Roberto ScatenaBruno Giardina
Dec 2, 2008·PPAR Research·David Bishop-Bailey, Karen E Swales
Jul 16, 2011·International Journal of Rheumatology·Ivan V Shirinsky, Valery S Shirinsky
Jan 15, 2013·PPAR Research·Osamu KimuraTooru Shimosegawa
Dec 3, 2011·Cancer Prevention Research·Mara H ShermanRonald M Evans
Dec 21, 2011·The Journal of Clinical Investigation·Dipak PanigrahyDarryl C Zeldin
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Cyrus V DesouzaVivian Fonseca
Sep 21, 2013·Vascular Pharmacology·Yasmeen Q RizviAdebayo Oyekan
Jul 11, 2008·PPAR Research·Jo A Van GinderachterPatrick De Baetselier
Aug 30, 2008·PPAR Research·Ambra Pozzi, Jorge H Capdevila
Jan 7, 2009·PPAR Research·Liliane Michalik, Walter Wahli
Sep 18, 2014·Current Treatment Options in Oncology·Albert AttiaMichael Chan
Sep 13, 2014·Glycoconjugate Journal·V B Sameer KumarP R Sudhakaran
Feb 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dana Greene-SchloesserMike E Robbins
Jun 2, 2012·PPAR Research·Joseph VamecqStéphane Rocchi
Sep 27, 2015·European Journal of Pharmacology·Jiaming GaoYongzhong Hou
Nov 23, 2011·Biochemical Society Transactions·David Bishop-Bailey
Jun 29, 2013·Current Eye Research·Jesper Skovlund JørgensenJakob Grauslund
Nov 13, 2014·Expert Opinion on Therapeutic Targets·Katarzyna PiwowarczykJarosław Czyż

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.